Canopy Growth Corp.’s stock continued rallying on Monday as it broke through the $1 level for the first time since May as cannabis optimism builds from retail investors in the wake of a historic move to re-schedule marijuana.
jumped nearly 40% to $1.30 a share, following through on a 23% rally in the previous session. At its current level, the stock is now up 137% in the past week. Between Sept. 1 and Sept. 8, the stock rose 69.4%, according to Dow Jones Market Data.
Among individual names, Curaleaf
was up by 8.8%, Verano
was up by 6.7%, Trulieve
was up by 7%, Green Thumb Industries
was up by 8%, Cresco Labs
was up by 5.7% and Tilray
was up by 6%.
A move by the Drug Enforcement Administration to review the Schedule I status of cannabis has fueled optimism in the sector in the past week.
The DEA is taking up the issue after the U.S. Department of Health and Human Services last week recommended that cannabis be re-classified to Schedule III, which would legalize cannabis for regulated medical use under federal law.
While there’s debate over how that will help cannabis companies, most experts agree that the 280E tax rule that prevents plant-touching businesses from writing off typical business expenses will no longer apply, in a boost to the business.
In other potential moves that could help the sector, Attorney General Merrick Garland has also said he’s working on an updated version of the Cole memo, which instructs federal law enforcement agencies to not interfere with state-run cannabis programs.
Some members of Congress are also optimistic that the SAFE Banking legislation to open up the financial system to cannabis could go to the Senate for a vote for the first time after 10 years.
Germany is also moving toward an adult-use cannabis program. On Wednesday, Canopy Growth said Canopy Growth Germany GmbH will operate under the name Canopy Medical in the German market, having previously been called Spectrum Therapeutics.
Cannabis stocks have been out of favor for institutional investors since most avoid contact with plant-touching businesses because of the current federal classification of pot as a Schedule I substance with no medical value.
That leaves the sector mostly in the realm of retail investors, who have mostly fled the sector in 2022 and 2023 partly because of a lack of movement on ending federal prohibition.
Jefferies analyst Owen Bennett said Monday that most of the upside in cannabis stock has been driven by retail investors.
“As we have explained before, the opportunity for stocks to potentially double again from here — and likely much more — is institutional involvement, which still remains minimal,” he said.